Imidazopyrazines as cyclin dependent kinase inhibitors
In its many embodiments, the present invention provides a novel class of imidazo[1,2-a] pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
1. A compound represented by the structural formula
wherein:
R is selected from the group consisting of alkyl. CF 3 , cycloalkyl, cycloalkylalkyl, arylalkyl, and —C(O)R 7 , wherein each of said alkyl, arylalkyl, and cycloalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, CF 3 , CN, —OCF 3 , —OR 6 , —C(O)R 7 , —NR 5 R 6 , —C(O 2 )R 6 ,—C(O)NR 5 R 6 , —(CHR 5 ) n OR 6 , —SR 5 , —S(O 2 )R 7 , —S(O 2 )NR 5 R 6 , —N(R 5 )S(O 2 )R 7 , —N(R 5 )C(O)R 7 and —N(R 5 )C(O)NR 5 R 6 ;
R 1 is H, halogen or alkyl;
R 2 is selected from the group consisting of H, halogen, CN, cycloalkyl, heterocyclyl, alkynyl and —CF 3 ;
R 3 is selected from the group consisting of aryl (with the exception of phenyl), heteroaryl (with the exception of furyl), heterocyclyl, —(CHR 5 ) n — heteroaryl, —S(O 2 )R 6 , —C(O)R 6 , —S(O 2 )NR 5 R 6 , —C(O)OR 6 , —C(O)NR 5 R 6 ,
wherein each of said aryl, heteroaryl and heterocyclyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF 3 , CN, —OCF 3 , —OR 5 , —NR 5 R 6 , —C(O 2 )R 5 , —C(O)NR 5 R 6 , —SR 6 , —S(O 2 )R 6 , —S(O 2 )NR 5 R 6 , —N(R 5 )S(O 2 )R 7 , —N(R 5 )C(O)R 7 and —N(R 5 )C(O)NR 5 R 6 , with the proviso that when R 3 is —(CHR 5 ) n -heteroaryl, R 2 can additionally be alkyl;
R 5 is H or alkyl;
R 6 is selected from the group consisting of H, alkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl, wherein each of said alkyl, heteroarylalkyl, aryl, heteroaryl and arylalkyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF 3 , OCF 3 , CN, —OR 5 , —NR 5 R 6 , —CH 2 OR 5 , —C(O 2 )R 5 , —C(O)NR 5 R 6 , —SR 6 , —S(O 2 )R 7 , —S(O 2 )NR 5 R 6 , —N(R 5 )S(O 2 )R 7 , —N(R 5 )C(O)R 7 and —N(R 5 )C(O)NR 5 R 6 ;
R 7 is selected from the group consisting of alkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl, wherein each of said alkyl, heteroarylalkyl, aryl, heteroaryl and arylalkyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF 3 , OCF 3 , CN, —OR 5 , —NR 5 R 6 , —CH 2 OR 5 , —C(O 2 )R 5 , —C(O)NR 5 R 6 , —SR 6 , —S(O 2 )R 7 , —S(O 2 )NR 5 R 6 , —N(R 5 )S(O 2 )R 7 , —N(R 5 )C(O)R 7 and —N(R 5 )C(O)NR 5 R 6 ;
R 8 is selected from the group consisting of R 6 , —C(O)NR 5 R 6 , —S(O 2 )NR 5 R 6 , —C(O)R 7 , —C(O 2 )R 6 , —S(O 2 )R 7 and —(CH 2 )-aryl;
m is 0 to 4; and
n is 1–4.
2. The compound of claim 1 , wherein R is selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl and arylalkyl, wherein each of said alkyl, cycloalkyl, and arylalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, CF 3 , CN, —OCF 3 , —OR 6 , —C(O)R 7 , —NR 5 R 6 , —C(O 2 )R 5 , —C(O)NR 5 R 6 , —SR 6 , —S(O 2 )R 7 , —S(O 2 )N R 5 R 6 , —N(R 5 )S(O 2 )R 7 , —N(R 5 )C(O)R 7 and —N(R 5 )C(O)NR 5 R 6 ;
R 1 is H or halogen;
R 2 is selected from the group consisting of H, halogen, cycloalkyl, CN, alkynyl and —CF 3 ;
R 3 is selected from the group consisting of aryl, heteroaryl, heterocyclyl, —(CHR 5 ) n -heteroaryl, —S(O 2 )R 6 , —C(O)R 6 , —S(O 2 )NR 5 R 6 , —C(O)OR 6 , —C(O)NR 5 R 6 ,
wherein each of said aryl, heteroaryl and heterocyclyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF 3 , CN, —OCF 3 , —N(R 5 )C(O)R 7 , —C(O)NR 5 R 6 , —S(O 2 )R 6 , and —N(R 5 )C(O)R 7 ;
R 5 is H or lower alkyl;
m is 0 to 2; and
n is 1 to 3.
3. The compound of claim 2 , wherein R is alkyl, arylalkyl or cycloalkylalkyl.
4. The compound of claim 3 , wherein R is selected from the group consisting of methyl, ethyl, t-butyl, cyclohexylmethyl, benzyl and phenethyl.
5. The compound of claim 2 , wherein R 1 is H.
6. The compound of claim 2 , wherein R 1 is methyl.
7. The compound of claim 2 , wherein R 2 is H, F, Cl, Br or I.
8. The compound of claim 7 , wherein R 2 is Br.
9. The compound of claim 8 , wherein R 3 is (pyrid-2-yl)methyl, (pyrid-3-yl)methyl, (pyrid-4-yl )methyl, thien-2-yl or thien-3yl, wherein said pyridyl and thienyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of F, Cl, Br, CF 3 , lower alkyl, methoxy and CN.
10. The compound of claim 9 , wherein R 3 is (pyrid-2-yl)methyl.
11. The compound of claim 9 , wherein R 3 is (pyrid-3-yl)methyl.
12. The compound of claim 9 , wherein R 3 is (pyrid-4-yl)methyl.
13. The compound of claim 2 , wherein m is 0.
14. The compound of claim 2 , wherein n is 1.
15. A compound of the formula:
or a pharmaceutically acceptable salt thereof.
16. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 in combination with at least one pharmaceutically acceptable carrier.
17. The pharmaceutical composition of claim 16 , additionally comprising one or more anti-cancer agents selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, CPT-11, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, 5FU, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphopramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.
18. A compound of claim 1 in purified form.